NCT00635778 2018-10-09
MK-0646-002
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
6 trialsNCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00759785 2018-08-15
MK-0646-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00925015 2018-08-15
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00694356 2018-08-08
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00701103 2018-08-08
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
Merck Sharp & Dohme LLC
Phase 1 Completed